{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:23:23Z","timestamp":1790461403000,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-20\\u20130158"],"award-info":[{"award-number":["APVV-20\\u20130158"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-24-0168"],"award-info":[{"award-number":["APVV-24-0168"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-21\\u20130197"],"award-info":[{"award-number":["APVV-21\\u20130197"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003194","name":"Agent\u00fara Ministerstva \u0160kolstva, Vedy, V\u00fdskumu a \u0160portu SR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002002","name":"Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["2\/0059\/25"],"award-info":[{"award-number":["2\/0059\/25"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["1\/0071\/24"],"award-info":[{"award-number":["1\/0071\/24"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["1\/0013\/25"],"award-info":[{"award-number":["1\/0013\/25"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["2\/0124\/21"],"award-info":[{"award-number":["2\/0124\/21"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118659","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:45:19Z","timestamp":1761266719000},"page":"118659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors"],"prefix":"10.1016","volume":"192","author":[{"given":"Nat\u00e1lia","family":"Udvorkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikt\u00f3ria","family":"Blahov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavl\u00edna","family":"Malch\u00e1rkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Jochov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katar\u00edna","family":"Ka\u013eavsk\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Fekia\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Hor\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"D\u017eongov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3256-6960","authenticated-orcid":false,"given":"Jakub","family":"Janko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Pastorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Chovanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"\u010cierna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ku\u010derov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118659_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-018-0029-0","article-title":"Testicular cancer","volume":"4","author":"Cheng","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118659_bib2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2024.27122","article-title":"Testicular germ cell tumors: a review","volume":"333","author":"Singla","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2025.118659_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11912-018-0730-x","article-title":"Molecular mechanisms of cisplatin chemoresistance and its circumventing in testicular germ cell tumors","volume":"20","author":"Schmidtova","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118659_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316872","article-title":"Biomarkers for salvage therapy in testicular germ cell tumors","volume":"24","author":"Urbini","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118659_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","article-title":"The rediscovery of platinum-based cancer therapy","volume":"21","author":"Rottenberg","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118659_bib6","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","article-title":"The cancer surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets","volume":"2","author":"Hu","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.biopha.2025.118659_bib7","doi-asserted-by":"crossref","first-page":"C362","DOI":"10.1152\/ajpcell.00200.2024","article-title":"Antibody-drug conjugates as a novel therapeutic modality to treat recurrent refractory germ cell tumors","volume":"327","author":"Udvorkova","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.biopha.2025.118659_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/CCO.0000000000001129","article-title":"Novel therapeutics in refractory germ cell tumors","volume":"37","author":"Richardson","year":"2025","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.biopha.2025.118659_bib9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s10637-022-01276-w","article-title":"A phase II study assessing the safety and efficacy of ASP1650 in Male patients with relapsed refractory germ cell tumors","volume":"40","author":"Adra","year":"2022","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.biopha.2025.118659_bib10","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118659_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8_ement_1","key":"10.1016\/j.biopha.2025.118659_bib12","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1158\/1538-7445.AM2025-2945","article-title":"Abstract 2945: PLB-002 is a novel claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer","volume":"85","author":"Pan","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2025.118659_bib13","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/j.annonc.2024.08.783","article-title":"Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors","author":"Konecny","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118659_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061845","article-title":"Target antigen attributes and their contributions to clinically approved Antibody-Drug conjugates (ADCs) in haematopoietic and solid cancers","volume":"15","author":"Esapa","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118659_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","article-title":"Antibody-drug conjugates in breast cancer: current evidence and future directions","volume":"14","author":"Li","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118659_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cells14040287","article-title":"Mirvetuximab soravtansine induces potent cytotoxicity and bystander effect in Cisplatin-Resistant germ cell tumor cells","volume":"14","author":"Kucerova","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118659_bib17","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4149\/neo_2024_240609N249","article-title":"Association between glutathione S-transferases M1 expression and treatment outcome in germ cell tumor patients","volume":"71","author":"Mego","year":"2024","journal-title":"Neoplasma"},{"key":"10.1016\/j.biopha.2025.118659_bib18","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody-Drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2025.118659_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10050972","article-title":"Overcoming chemotherapy resistance in germ cell tumors","volume":"10","author":"Orszaghova","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118659_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104241","article-title":"Antibody-drug conjugates: prospects for the next generation","author":"Grairi","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118659_bib21","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10020-023-00636-3","article-title":"Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options","volume":"29","author":"Skowron","year":"2023","journal-title":"Mol. Med"},{"key":"10.1016\/j.biopha.2025.118659_bib22","article-title":"Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study","author":"Ricci","year":"2025","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2025.118659_bib23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"key":"10.1016\/j.biopha.2025.118659_bib24","article-title":"Trop2: jack of all trades","volume":"12","author":"Lenart","year":"2020","journal-title":"Master Non Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118659_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118659_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105815","article-title":"Assessment of trophoblast cell-surface antigen 2 (TROP2) and nectin-4 expression in choriocarcinoma","volume":"159","author":"Tekin","year":"2025","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.biopha.2025.118659_bib27","series-title":"2025 ASCO Annual Meeting, Journal of Clinical Oncology","first-page":"5031","article-title":"TROP2 expression in germ cell tumors (GCT)","author":"Richardson","year":"2025"},{"key":"10.1016\/j.biopha.2025.118659_bib28","doi-asserted-by":"crossref","first-page":"33658","DOI":"10.1038\/srep33658","article-title":"Impact of TROP2 expression on prognosis in solid tumors: a systematic review and Meta-analysis","volume":"6","author":"Zeng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118659_bib29","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118659_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2020.05.040","article-title":"HIF1\u03b1 inhibitor 2-methoxyestradiol decreases NRN1 expression and represses in vivo and in vitro growth of patient-derived testicular germ cell tumor spheroids","volume":"489","author":"Namekawa","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.118659_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bjc.66000524","article-title":"Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German testicular cancer study group","volume":"87","author":"Kollmannsberger","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118659_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eururo.2004.03.001","article-title":"Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study","volume":"46","author":"Pectasides","year":"2004","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2025.118659_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010087","article-title":"Impact of spatially heterogeneous Trop-2 expression on prognosis in oral squamous cell carcinoma","volume":"23","author":"Erber","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118659_bib34","article-title":"Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: a pilot study","volume":"44","author":"LeVee","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118659_bib35","doi-asserted-by":"crossref","first-page":"1495675","DOI":"10.3389\/fimmu.2024.1495675","article-title":"Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions","volume":"15","author":"Tong","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2025.118659_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40259-024-00643-8","article-title":"Could a Long-Acting prodrug of SN-38 be efficacious in sacituzumab Govitecan-Resistant tumors?","volume":"38","author":"Santi","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2025.118659_bib37","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and Cross-Resistance to Antibody-Drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118659_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2025.118659_bib39","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","article-title":"FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer","volume":"27","author":"Wahby","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118659_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11523-024-01036-1","article-title":"Sacituzumab govitecan: a review in unresectable or metastatic HR+\/HER2\u2212 breast cancer","volume":"19","author":"Kang","year":"2024","journal-title":"Target. Oncol."},{"key":"10.1016\/j.biopha.2025.118659_bib41","doi-asserted-by":"crossref","first-page":"1624386","DOI":"10.3389\/fonc.2025.1624386","article-title":"Efficacy and safety of sacituzumab govitecan in solid tumors: a systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:43:41Z","timestamp":1775781821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":41,"alternative-id":["S0753332225008534"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118659","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of sacituzumab govitecan in recurrent refractory germ cell tumors","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118659"}}